abcl-20250910
0001703057falseVancouverBC00017030572025-09-102025-09-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 10, 2025
__________________________________________
AbCellera Biologics Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
British Columbia001-39781Not Applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue
Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o


Item 8.01    Other Events
On September 10, 2025, AbCellera Biologics Inc. (the “Company”), issued a press release announcing the appointment of Sarah Noonberg, M.D., Ph.D., as the Company’s Chief Medical Officer. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01    Financial Statements and Exhibits
(d)Exhibits
Exhibit
No.		Description
99.1
104Cover Page Interactive Data File (embedded as Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 10, 2025ABCELLERA BIOLOGICS INC.
 
By:/s/ Carl L. G. Hansen
Carl L. G. Hansen, Ph.D.
Chief Executive Officer and Director
(Principal Executive Officer)

150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Appoints Dr. Sarah Noonberg as Chief Medical O�cer 2025-09-10 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical O�cer. Dr. Noonberg, a board-certi�ed physician-scientist, brings over two decades of industry experience leading development programs from discovery through to global regulatory approvals and commercialization across a diverse range of indications and therapeutic modalities, including oncology, neuroscience, rare diseases, gene therapy, and cell therapy. As Chief Medical O�cer, Dr. Noonberg, will leverage her clinical development background to advance AbCellera’s pipeline of antibody-based therapeutics. “We are pleased to welcome Sarah as AbCellera’s �rst Chief Medical O�cer,” said Carl Hansen, PhD, founder and CEO of AbCellera. “With more than 20 years of experience in clinical development, Sarah brings deep expertise and proven operational and leadership strength that will be invaluable as we continue to build and advance our clinical pipeline.” “I'm honored to join AbCellera at such an exciting time as it transitions to a clinical stage company,” said Dr. Noonberg. “I look forward to working with the team to advance a growing portfolio of important therapies that have the potential to improve patient's lives." Dr. Noonberg was most recently the Chief Medical O�cer of Metagenomi, where she led the translation of its gene editing platform into a pipeline strategy and contributed to its ~$100M initial public offering. Prior to Metagenomi, Dr. Noonberg served as Chief Medical O�cer at multiple companies, including Maze Therapeutics, Nohla Therapeutics, and Prothena Biosciences; as Group Vice President and Head of Global Clinical Development at BioMarin; and as Senior Vice President at Medivation, where she contributed to the development of enzalutamide 1

 
(XTANDI™) for prostate cancer. Dr. Noonberg is currently a board member of Neurogene and a past board member of Marinus Pharmaceuticals and Protagonist Therapeutics. Dr. Noonberg received her M.D. from the University of California, San Francisco, her Ph.D. in Bioengineering from the University of California, Berkeley, and completed her internal medicine residency at the Johns Hopkins Hospital. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology. For more information, please visit www.abcellera.com. Inquiries Media: Tiffany Chiu; [email protected], +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005 Investor Relations: Peter Ahn; [email protected], +1(778)729-9116 Source: AbCellera Biologics Inc. 2